Equities

cbdMD Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

cbdMD Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.7537
  • Today's Change-0.057 / -7.05%
  • Shares traded660.88k
  • 1 Year change-82.83%
  • Beta2.1507
Data delayed at least 15 minutes, as of Feb 11 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.

  • Revenue in USD (TTM)19.19m
  • Net income in USD-4.38m
  • Incorporated2015
  • Employees42.00
  • Location
    cbdMD Inc8845 Red Oak BlvdCHARLOTTE 28217-5593United StatesUSA
  • Phone+1 (704) 445-3060
  • Websitehttps://www.cbdmd.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
YCBD:ASQ since
announced
Transaction
value
Gaia Botanicals LLCDeal completed12 Jan 202612 Jan 2026Deal completed-29.56%1.02m
Data delayed at least 15 minutes, as of Feb 11 2026 21:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sunshine Biopharma Inc37.32m-5.99m5.89m52.00--0.226--0.1577-2.03-2.0310.745.311.212.0910.12717,764.30-19.47-68.65-23.80-89.0233.0132.79-16.06-81.122.09-209.950.00--44.75340.11-13.94--370.33--
LakeShore Biopharma Co Ltd88.99m-14.47m6.63m573.00--0.04620.99640.0745-0.7487-0.74874.643.480.4270.50011.30155,302.20-6.94---15.95--82.47---16.26--0.7452-2.630.453--7.24--76.93------
CV Sciences Inc14.37m-1.48m6.71m47.00--4.36--0.4669-0.008-0.0080.0780.00841.871.6734.74305,659.60-19.21-44.92-66.32-105.3247.0442.89-10.29-49.080.2125-2.020.3829---1.87-21.80-177.18---56.43--
Tian'an Pharmaceutical Co Ltd10.65m3.14m8.00m--0.04450.00972.200.75110.22460.22460.76111.03----------------68.54--29.51--13.3625.660.00--50.51--106.71------
cbdMD Inc19.19m-4.38m8.51m42.00--1.00--0.4435-3.92-3.924.770.81041.832.8318.96---19.44-48.27-44.42-54.9962.3763.95-10.63-85.601.20--0.00---1.50-14.4543.21---32.56--
Gelteq Ltd117.18k-4.70m8.57m7.00--0.7664--73.13-0.4981-0.49810.01241.040.0078--0.515516,740.08-31.47-17.38-40.60-19.16-----4,011.74-4,507.46---3.520.2106-------87.40------
Biofrontera Inc37.17m-17.57m9.09m92.00------0.2445-1.84-1.844.07-0.22162.192.449.45403,967.40-103.57-48.03-339.69-77.5564.4148.93-47.28-60.990.8033-47.482.37--9.547.3511.78---35.51--
Cuprina Holdings (Cayman) Ltd23.99k-2.24m9.42m14.00--1.55--392.50-0.1232-0.12320.00130.2830.004913.390.79761,713.68-44.56---131.50---69.27---9,194.46--3.58-306.250.0244---52.05---39.39------
Integrated Biopharma Inc53.43m672.00k9.94m153.0015.100.484910.040.1860.02120.02121.710.65972.074.4512.77349,183.002.609.983.2813.689.7510.741.264.581.92--0.0072--8.020.5933482.30-30.67-0.8556--
Lotus Pharmaceuticals Inc70.79m1.72m10.05m233.000.06870.00112.600.1420.05530.05532.563.580.632137.2717.85303,836.901.5522.841.7126.4035.1041.622.4519.930.442830.800.05160.0028.7131.70-12.2251.1170.48--
Bon Natural Life Ltd18.67m-1.99m10.05m96.0018.520.2302--0.53850.0880.0886.747.080.25416.071.64194,486.40-2.795.82-3.977.8620.7728.53-10.9810.831.61-4.440.17350.00-21.700.4899-577.58--18.20--
Nexgel Inc11.67m-2.88m10.75m19.00--2.07--0.9215-0.3796-0.37961.530.63691.053.7913.46613,947.40-25.14-39.08-36.83-49.7938.3019.60-23.91-105.401.08-51.360.1439--112.4764.69-3.93------
Akari Therapeutics PLC (ADR)0.00-15.77m11.08m8.00---------0.600-0.6000.00--0.00----0.00-65.57-112.46-136.47-257.78-----------27.770.0854-------97.75------
Data as of Feb 11 2026. Currency figures normalised to cbdMD Inc's reporting currency: US Dollar USD

Institutional shareholders

5.02%Per cent of shares held by top holders
HolderShares% Held
CSS LLCas of 30 Sep 2025142.62k1.59%
Chapin Davis, Inc. (Investment Management)as of 31 Dec 202581.25k0.91%
Alesco Advisors LLCas of 31 Dec 202568.51k0.77%
The Vanguard Group, Inc.as of 31 Dec 202551.05k0.57%
Vanguard Fiduciary Trust Co.as of 31 Dec 202547.16k0.53%
Commonwealth Equity Services LLCas of 30 Sep 202516.26k0.18%
Scientech Research LLCas of 30 Sep 202515.41k0.17%
Sassicaia Capital Advisers LLCas of 30 Sep 202512.00k0.13%
UBS Securities LLCas of 31 Dec 202510.15k0.11%
Harbour Investments, Inc.as of 30 Sep 20255.20k0.06%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.